ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 364
- Registration Number
- NCT03821935
- Locations
- 🇮🇱
Rabin Medical Center /ID# 258479, Petah Tikva, Israel
🇨🇳Taipei Veterans General Hosp /ID# 257635, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital /ID# 265551, Taoyuan City, Taiwan
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT03818542
- Locations
- 🇺🇸
Massachusetts General Hospital /ID# 207392, Boston, Massachusetts, United States
🇺🇸University of Michigan /ID# 210181, Ann Arbor, Michigan, United States
🇺🇸MD Anderson Cancer Center /ID# 208749, Houston, Texas, United States
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaNon-Hodgkin's LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT03797261
- Locations
- 🇺🇸
USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States
🇺🇸Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States
🇦🇺Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03785184
- Locations
- 🇦🇺
St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia
🇨🇦Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada
🇦🇺Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
- Conditions
- Post-Operative Atrial Fibrillation
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 323
- Registration Number
- NCT03779841
- Locations
- 🇺🇸
University of Maryland Medical Center /ID# 234352, Baltimore, Maryland, United States
🇦🇹Medizinische Universitaet Wien /ID# 238259, Vienna, Wien, Austria
🇺🇸Stanford University School of Med /ID# 236922, Stanford, California, United States
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 244
- Registration Number
- NCT03781167
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau /ID# 208240, Barcelona, Spain
🇺🇸Northwestern University Feinberg School of Medicine /ID# 208812, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital /ID# 207993, Boston, Massachusetts, United States
Expanded Access to ABBV-8E12
- Conditions
- Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03744546
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
- Conditions
- Hepatitis C
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3134
- Registration Number
- NCT03740230
- Locations
- 🇰🇷
Kwangju Christian Hospital /ID# 210623, Gwangju, Jeonranamdo, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center /ID# 210610, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Wonkwang University Hospital /Id# 210620, Iksan, Jeonrabugdo, Korea, Republic of
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 123
- Registration Number
- NCT03737812
- Locations
- 🇺🇸
Central Texas Neurology Consul /ID# 203108, Round Rock, Texas, United States
🇨🇦Montreal Neurological Institut /ID# 203868, Montreal, Quebec, Canada
🇨🇦Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 203869, Montreal, Quebec, Canada
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 759
- Registration Number
- NCT03738215
- Locations
- 🇺🇸
Lehigh Center for Clinical Research /ID# 236702, Allentown, Pennsylvania, United States
🇺🇸Hassman Research Institute /ID# 237501, Berlin, New Jersey, United States
🇺🇸Psych Atlanta /ID# 235835, Marietta, Georgia, United States